Non-invasive assessment of liver function: Trying not to miss an opportunity

Alimentary Pharmacology and Therapeutics

Volumn 19, Issue 7, 2004, Pages 827-828

  Giannini, E G ^a   Testa, R ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BREATH ANALYSIS; DECISION MAKING; DISEASE SEVERITY; HEPATITIS C; HUMAN; LETTER; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FUNCTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

AMINOPYRINE; BREATH TESTS; GALACTOSE; HUMANS; LIVER DISEASES; LIVER FUNCTION TESTS;

EID: 1942534211     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.01915.x     Document Type: Letter

References (7)

1. 13C-galactose breath test as a measure of liver function. Aliment Pharmacol Ther 2003; 18: 995-1002.
2. Testa R, Caglieris S, Risso D, et al. Monoethylglycinexylidide formation measurement as a hepatic function test to assess severity of chronic liver disease. Am J Gastroenterol 1997; 92: 2268-73.
3. 13C-aminopyrine breath test to evaluate severity of disease in patients with chronic hepatitis C virus infection. Aliment Pharmacol Ther 2002; 16: 717-25.
4. 13C-Galactose breath test: correlation with liver fibrosis in chronic hepatitis C. Eur J Clin Invest 1999; 29: 624-9.
5. 2. Gastroenterology 1976; 71: 98-101.
6. Giannini E, Fasoli A, Botta F, et al. Is there a role for multiple quantitative liver function tests? Dig Liver Dis 2000; 32: 644.
7. Bircher J. Quantitative assessment of deranged hepatic function: a missed opportunity? Semin Liver Dis 1983; 3: 275-84.